1 out of every 4 Americans is vulnerable to severe #COVID19 infection, according to analysis from C.Troeger @IHME_UW on @ThinkGlobalHlth
This includes 50M Americans who are over 65, many of whom live in states set to lift social distancing policies 2/ thinkglobalhealth.org/article/high-r…
It includes US adults (ages 20-64) more vulnerable to #COVID19 due to underlying conditions like sickle cell disease), HIV, chronic kidney disease, leukemia, lymphoma, and other cancers #NCDs
63 million Americans ages 19 to 64 smoke or suffer from alcoholism, diabetes, or #NCDs like chronic heart, liver, or lung diseases like asthma. They too are a higher risk from #COVID19
The US has most outstanding, but that is misleading as President Biden just this week added 500m to US total pledged donation by 1.1B COVID vaccine doses
Maximizing potential benefit of vaccine donations depends on doses going where they can do the"most good" but there's no consensus on where that would be
This week's summit in Cornwall, UK should be the time when G7 leaders finally act on their promises to send surplus COVID-19 vaccine supplies to the many other countries where they remain scarce #G7UK
COVAX has been criticized by @ZekeEmanuel@GovindPersad & others for its population-based allocation scheme that does not direct most of its early vaccine supplies to the settings at the greatest risk of otherwise having high COVID-19 death rates 3/ nytimes.com/2021/05/24/opi…
Results published in Lancet indicate say this a/b 1 dose regimen
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection thelancet.com/journals/lance…
Apparently, Oxford/AstraZeneca has not even filed a submission package with EMA yet. FDA decision isn't coming soon either.
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it reuters.com/article/us-hea…